Sunesis Pharmaceuticals to Present at Upcoming Investor Conferences
March 14 2018 - 4:05PM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that
the Company will present at two upcoming investor conferences.
Willie Quinn, Chief Financial Officer and Senior
Vice President, Finance and Corporate Development of Sunesis, will
present at the Oppenheimer 28th Annual Healthcare Conference on
Wednesday, March 21, 2018 at 8:35 AM Eastern Time at the Westin
Grand Central Hotel in New York City.
Mr. Quinn will also present at the Needham &
Company’s 17th Annual Healthcare Conference on Tuesday, March 27,
2018 at 8:00 AM Eastern Time at the Westin Grand Central Hotel in
New York City.
Live webcasts of the presentations will be
available on the Sunesis website at http://ir.sunesis.com. A
replay of each webcast will be archived on the "Calendar of Events"
page in the Investors and Media section of the Sunesis website for
two weeks.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company
developing new therapeutics for the treatment of solid and
hematologic cancers. Sunesis has built an experienced cancer drug
development organization committed to improving the lives of people
with cancer. The Company is focused on advancing its novel
kinase-inhibitor pipeline, with an emphasis on establishing proof
of concept that its oral non-covalent BTK-inhibitor vecabrutinib is
effective in ibrutinib-resistant chronic lymphocytic leukemia.
Vecabrutinib is currently being evaluated in a Phase 1b/2 study in
adults with chronic lymphocytic leukemia and other B-cell
malignancies who have progressed after prior therapies. Beyond the
development of vecabrutinib, the Company has two other kinase
inhibitor programs, including the Takeda-partnered pan-RAF
inhibitor TAK-580, which is in clinical trials for solid tumors,
and Sunesis’ proprietary preclinical PDK1 inhibitor SNS-510, which
is in preclinical development with an IND submission planned in
2019. PDK1 is a master kinase that activates other kinases
important to cell growth and survival including members of the AKT,
PKC, RSK and SGK families.
For additional information on Sunesis, please
visit www.sunesis.com.
SUNESIS and the logos are trademarks
of Sunesis Pharmaceuticals, Inc.
|
Investor and Media
Inquiries:Maeve ConneightonArgot Partners212-600-1902 |
|
Willie
QuinnSunesis Pharmaceuticals Inc.650-266-3716 |
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Apr 2023 to Apr 2024